Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support

Anaesthesia and Intensive Care

Volumn 41, Issue 1, 2013, Pages 66-73

  Mulla, H ^a,b   Peek, G J ^a,c   Harvey, C ^a,c   Westrope, C ^a,c   Kidy, Z ^a,b   Ramaiah, R ^a,c  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b Department of Pharmacy ^*  (United Kingdom)

^c Heartlink ECMO Centre   (United Kingdom)

Author keywords

ECMO; H1N1 influenza; Neuraminidase inhibitors; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CREATININE; OSELTAMIVIR; POLYVINYLCHLORIDE; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLOOD PUMP; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FEMALE; FIRST PASS EFFECT; HUMAN; INFLUENZA A (H1N1); MALE; OPEN STUDY; PROSPECTIVE STUDY; RESPIRATORY FAILURE; STEADY STATE; TUBE; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; NONLINEAR SYSTEM; TISSUE DISTRIBUTION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CREATININE; CRITICAL ILLNESS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; OSELTAMIVIR; TISSUE DISTRIBUTION;

MLCS; MLOWN;

EID: 84874408877     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1304100112     Document Type: Article

References (18)

1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122:2731-2740.
2. Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A (H1N1). JAMA 2011; 306:1659-1668.
3. Davies BE. Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65:ii5-ii10.
4. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012; 27:741.e9-741.e18.
5. Mulla H, Lawson G, Firmin RK, Upton DR. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatr Perinat Drug Ther 2001; 4:109-120.
6. L emaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Corvol E et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit 2012; 34:171-175.
7. Wildschut ED, de Hoog M, Ahsman MJ, Tibboel D, Osterhaus AD, Fraaij PL. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One 2010; 5:e10938.
8. Karlsson MO, Holford N. A tutorial on visual predictive checks. PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe 2008; 17:1434. From www.page-meeting.org/?abstract=1434.
9. Bouchard J, Macedo E, Soroko S, Chertow GM, Himmelfarb J, Ikizler TA et al. Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2010; 25:102-107.
10. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008; 48:935-947.
11. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37:471-484.
12. WHO guidelines for pharmacologic management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization 2009. From www.who.int/csr/resources/ publications/swineflu/h1n1-use-antivirals-20090820/ en.
13. Dutkowski R. Oseltamivir in seasonal influenza: Cumulative experience in low- and high-risk patients. J Antimicrob Chemother 2010; 65:ii11-ii24.
14. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-363.
15. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34:25-56.
16. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30:2145-5216.
17. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of betalactams. Crit Care 2011; 15:R206.
18. Hall RJ, Peacey MP, Ralston JC, Bocacao J, Ziki M, Gunn W et al. Pandemic influenza A (H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir. Euro Surveill 2009; 14:19282.